# Asthma Devices Market

> Asthma Device Market Research Report Information By Type (Inhalers, Nebulizers, Dry Powder Inhalers, Metered-Dose Inhalers, Mesh Nebulizers) By Technology (Manually Operated, Digitally Operated) By End Users (Hospital, Retail Pharmacies) -Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.71%
- **2024:** $ 4.27 Billion
- **2025:** $ 4.56 Billion
- **2035:** $ 8.72 Billion
- **Key Players:** Companies such as GlaxoSmithKline(GB), AstraZeneca (GB), Boehringer Ingelheim (DE), Novartis (CH), Teva Pharmaceutical Industries (IL), Merck & Co. (US), Sanofi (FR), Roche (CH), Philips (NL), Omron Healthcare (JP) are some of the major participants in the global market.

**Report ID:** MRFR/MED/1093-HCR · **Pages:** 90 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/asthma-devices-market-1624

---

## Market Summary

## **Global Asthma Devices Market Overview**

Asthma Devices Market Size was valued at USD 4.00 Billion in 2023. The Global Asthma Devices industry is projected to grow from USD 4.21 Billion in 2024 to USD 7.45 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032).Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease.

Increasing prevalence of asthma is one of the major drivers for the market growth.

According to the World Health Organization in 2017, approximately 235 million people suffered from asthma. Moreover, it was estimated that in 2015, the disease killed approximately 383 million patients around the globe. Additionally, rising healthcare expenditures and increasing awareness fuel the market growth. However, long treatment procedures and low per capita income followed by lack of favorable reimbursement policies in the developing countries will restrain the market growth during the forecast period. 

The UK-based medical device company Acurable disclosed this in October 2022, saying it was helped to raise $10.8 million by its lead investor for the round, Kibo Ventures. The firm will use the funding to speed up AcuPebble SA100, which is a home-based sleep diagnostic tool that helps identify and track obstructive [sleep apnea](../../../reports/sleep-apnea-devices-market-2061) cases around the world. Moreover, Acurable would develop new drugs for cardiovascular diseases, asthma and COPD.

Adherium Limited has partnered with Trudell Medical Limited in August 2022 to treat U.S. patients with COPD.A US$350 million Series A funding round was won by Arteria Therapeutics, a biotechnology company committed to helping asthmatics live normal lives in July of 2022.

This money was expected by the company to fund phase 3 trials for a new asthma candidate that is said to have biologic-like efficacy in treating asthma through oral delivery.Alkem launched Innohaler, a DPI device in March 2022 with an aim of improving comfort living for Asthma and COPD (Chronic Obstructive Pulmonary Disease) patients and narrowing the existing gaps in Asthma care across India.

The introduction of this device marks Alkem’s entry into core inhalation treatments where it expects better medication will reach the lungs with every inhalation due to increased patient awareness and adherence program.Life Wellness Healthcare announced an update on their online store that allows individuals with chronic obstructive pulmonary disease (COPD) be able to reduce their symptoms at home as of January 2022.

Payment plans are available when purchasing AirPhysio devices, which are now ready for shipment throughout the United States.For example, in March 2022, the US Food and Drug Administration approved Symbicort Inhalation Aerosol’s first generic version for treating two common pulmonary conditions, including asthma, among six-year-old and older patients.For example, a Phase III clinical trial evaluating budesonide/glycopyrronium/formoterol inhalers effectiveness and safety among adults and adolescents who suffer from severe asthma and are inadequately controlled with the standard of care was initiated in March 2021 by AstraZeneca PLC in Mexico and the United States.

The trial is expected to be completed in September 2023.

## **Asthma Devices Market Segment Insights**

The global asthma devices market is segmented on the basis of type, technology, and end users.

### ** ****Asthma Devices Type Insights**** **

On the basis of the type, the market is segmented into inhalers, nebulizers, and others. The inhalers segment is sub-segmented into metered-dose inhalers and dry powder inhalers. The metered-dose inhalers segment, by inhalers, is further categorized into standard pressurized metered-dose inhalers, breath-activated pressurized metered-dose inhalers, metered-dose inhalers with a spacer, and others. The nebulizers segment is sub-segmented into compressor nebulizers, ultrasonic nebulizers, mesh nebulizers, and others.

### **Asthma Devices Technology Insights**

** ** On the basis of technology, the asthma devices market is segmented into manually operated inhaler devices, digitally operated inhaler devices, and others.

### **Asthma Devices End-User Insights**

** ** On the basis of end users, the market is segmented into hospital, clinics, retail pharmacies, and others.

### **Asthma Devices Regional Insights** 

The Americas dominate the global asthma devices market owing to a well-developed healthcare sector and huge patient population for asthma diseases. According to the Centres for Disease Control and Prevention, in 2015, approximately, 7.8% of the total population in the U.S. was identified for the presence of asthma. Moreover, changing lifestyle and increasing healthcare expenditure fuels the market growth. Additionally, the presence of global players like Merck & Co., Inc. and Baxter, and others boost market growth during the forecast period.   Europe is the second largest asthma devices market owing to a well-developed healthcare infrastructure and huge patient population.

Moreover, government support for research & development and rising healthcare expenditures fuel the market growth. According to a study published in the Asthma Research and Practice journal in 2017, the yearly estimated cost for all the asthmatics per patient is about USD 1,900. Additionally, the presence of the developed economies like the U.K, Germany, and France within the region boosts the market growth.    Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China.

According to a study of the Indian Chest Society in 2015, 300 million people suffered from asthma worldwide and about a tenth of its share is in India. Moreover, as per the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020.

Moreover, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax along boosts the market growth.    On the other hand, the Middle East & Africa holds the least share of the global asthma devices market due to the presence of poor economy, especially within the African region. The absence of the developed healthcare sector and stringent government policies restrain the market growth within the African region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures. 

## **Key players for Asthma Devices Market**

- GlaxoSmithKline plc. (Europe)
- Merck & Co., Inc. (U.S.)
- 3M (U.S.)
- Aristopharma Ltd. (Asia Pacific)
- SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific)
- [AstraZeneca](https://www.astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html) (Europe)
- Baxter. (U.S.)
- Boehringer Ingelheim GmbH (Europe)
- Koninklijke Philips N.V. (Europe)

### **Intended Audience**

- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers 

## Market Drivers

### Rising Prevalence of Asthma

The increasing prevalence of asthma worldwide is a primary driver for The Global Asthma Devices Industry. According to recent estimates, approximately 300 million individuals are affected by asthma globally, with this number projected to rise. This growing patient population necessitates the development and distribution of effective asthma management devices, such as inhalers and nebulizers.
 
The demand for these devices is further fueled by the need for improved patient outcomes and adherence to treatment regimens. As healthcare systems strive to manage this chronic condition more effectively, the global market for asthma devices is likely to expand significantly, reflecting the urgent need for innovative solutions to address the challenges faced by asthma patients.
 

- According to the World Bank, global healthcare expenditure continues to increase as countries strengthen chronic disease management programs. Expanding investment in respiratory healthcare infrastructure and universal health coverage is improving patient access to asthma diagnosis and treatment, supporting growing adoption of inhalers, nebulizers, and other asthma management devices worldwide.

### Increased Awareness and Education

Increased awareness and education regarding asthma management are pivotal drivers for The Global Asthma Devices Industry. Public health campaigns and educational initiatives have significantly improved understanding of asthma, its triggers, and the importance of proper device usage. This heightened awareness has led to a greater demand for asthma devices, as patients are more informed about their treatment options.
 
Furthermore, healthcare professionals are increasingly emphasizing the need for effective asthma management, which includes the use of appropriate devices. As a result, the global market is witnessing a surge in demand for inhalers, spacers, and nebulizers, reflecting the positive impact of education on patient behavior and device utilization.
 

- PubMed studies consistently demonstrate that structured asthma education programs significantly improve inhaler technique, medication adherence, and disease control. Clinical evidence shows that patients receiving regular asthma education experience fewer exacerbations and hospitalizations, encouraging healthcare providers to promote advanced asthma devices alongside patient-centered disease management strategies.

### Regulatory Support for Innovative Devices

Regulatory support for innovative asthma devices is an essential driver for The Global Asthma Devices Industry. Regulatory bodies are increasingly recognizing the importance of facilitating the approval process for new and advanced asthma management devices. This support encourages manufacturers to invest in research and development, leading to the introduction of novel products that meet the evolving needs of patients.
 
As regulatory frameworks become more conducive to innovation, the market is likely to see a surge in the availability of cutting-edge asthma devices. This trend not only enhances competition among manufacturers but also provides patients with a wider array of options for effective asthma management.

### Technological Innovations in Device Design

Technological innovations play a crucial role in shaping The Global Asthma Devices Industry. The introduction of smart inhalers, which integrate digital health technologies, has transformed the way asthma is managed. These devices not only deliver medication but also track usage patterns and provide feedback to patients and healthcare providers.
 
The global market for smart inhalers is expected to grow substantially, with projections indicating a compound annual growth rate of over 20% in the coming years. Such advancements enhance patient engagement and adherence, ultimately leading to better asthma control. As technology continues to evolve, the demand for sophisticated asthma devices is likely to increase, driving market growth.

### Growing Investment in Healthcare Infrastructure

The growing investment in healthcare infrastructure across various regions is a notable driver for The Global Asthma Devices Industry. Governments and private entities are increasingly allocating resources to enhance healthcare facilities and improve access to asthma management solutions. This investment is particularly evident in developing countries, where the establishment of new healthcare centers and the procurement of medical devices are on the rise.
 
As healthcare systems expand, the availability of asthma devices is likely to increase, facilitating better access for patients. This trend is expected to contribute to market growth, as more individuals gain access to essential asthma management tools.

## Future Outlook

The Asthma Devices Market size is projected to reach USD 8.72 Billion by 2035, growing at a CAGR of 6.71%, driven by technological advancements, increasing prevalence of asthma, and rising healthcare expenditure.

**New opportunities:**

- Development of smart inhalers with real-time monitoring capabilities. Expansion into emerging markets with tailored asthma management solutions. Partnerships with telehealth platforms for integrated patient care services.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Inhalers (Largest) vs. Nebulizers (Fastest-Growing)

In the Global Asthma Devices Market, inhalers dominate the segment, representing the largest market share of 68% due to their widespread adoption and ease of use. Inhalers are the preferred choice for many patients managing asthma and chronic obstructive pulmonary disease (COPD), owing to their portability and convenience. Conversely, nebulizers, although smaller in market share, are emerging rapidly as a favored option, particularly among children and patients with severe asthma, leading to their recognition as the fastest-growing segment.

Novartis continues strengthening respiratory care through innovative inhalation therapies and strategic research initiatives. The company invested USD 9.3 billion in R&D during 2024, supporting the development of advanced respiratory medicines. Continued innovation in asthma treatment improves patient outcomes while reinforcing the widespread adoption of inhaler-based drug delivery systems globally.

### By Technology: Manually Operated Inhaler Devices (Largest) vs. Digitally Operated Inhaler Devices (Fastest-Growing)

In the Global Asthma Devices Market, the technology segment is primarily dominated by Manually Operated Inhaler Devices, which account for the largest market share of 72%. These devices have been a staple in asthma management due to their simplicity and effectiveness, making them highly preferred among patients and healthcare providers. Conversely, Digitally Operated Inhaler Devices are emerging as a significant force in the market, with a growing share as awareness of digital health solutions increases among asthma sufferers.

Teva Pharmaceutical Industries continues expanding its respiratory portfolio through innovative inhalation technologies and generic respiratory medicines. Operating in more than 60 markets, the company supports broader patient access to affordable asthma therapies. Continuous investment in inhaler technologies enhances treatment accessibility and strengthens demand for manually operated inhaler devices worldwide.

### By End User: Clinics (Largest) vs. Retail Pharmacies (Fastest-Growing)

In the Global Asthma Devices Market, the distribution of market share among end users reveals that clinics hold the largest segment, accounting for 46%, significantly influencing the overall utilization of asthma devices. Hospitals also represent a considerable share, leveraging their expansive facilities to cater to severe asthma cases. Meanwhile, retail pharmacies and other emerging end users are gradually claiming their space, indicating a diversification in purchasing avenues for asthma management solutions.

Merck & Co. continues supporting respiratory disease management through research-driven innovation and strategic healthcare collaborations. In 2024, the company invested approximately USD 17.9 billion in research and development, advancing respiratory therapies and improving clinical care. These investments strengthen clinics' role as the primary setting for asthma diagnosis, treatment, and long-term disease management.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America is the largest market for asthma devices, holding approximately 40% of the global share. The region benefits from advanced healthcare infrastructure, high prevalence of asthma, and increasing awareness about respiratory diseases. Regulatory support from agencies like the FDA has accelerated the approval of innovative devices, driving market growth. The demand for smart inhalers and connected devices is also on the rise, reflecting a shift towards personalized healthcare solutions.

- According to the CDC, approximately 24.9 million people in the United States are living with asthma, including about 4.7 million children. The substantial patient population continues to drive demand for advanced inhalers, nebulizers, and connected respiratory devices, reinforcing North America's leadership in the global market.

The United States is the leading country in this region, with significant contributions from Canada. Major players such as Merck & Co., GlaxoSmithKline, and AstraZeneca are heavily invested in research and development, enhancing their product offerings. The competitive landscape is characterized by strategic partnerships and collaborations aimed at improving patient outcomes. The presence of established healthcare systems further supports the growth of asthma devices in North America.

- Merck & Co. continues expanding respiratory research through sustained innovation and strategic healthcare collaborations. The company invested approximately USD 17.9 billion in R&D during 2024, supporting the development of innovative respiratory therapies and digital healthcare solutions that strengthen North America's advanced asthma care ecosystem and accelerate adoption of next-generation asthma devices.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for asthma devices, accounting for approximately 30% of the global market share. The region is witnessing growth driven by increasing asthma prevalence, supportive regulatory frameworks, and rising healthcare expenditures. The European Medicines Agency (EMA) has been proactive in approving innovative asthma devices, which has catalyzed market expansion. Additionally, the focus on preventive healthcare and patient education is enhancing demand for effective asthma management solutions.

Leading countries in Europe include Germany, France, and the UK, where significant investments in healthcare technology are evident. Key players like Boehringer Ingelheim and Novartis are focusing on developing advanced inhalation therapies. The competitive landscape is marked by innovation and collaboration among pharmaceutical companies and healthcare providers, aiming to improve patient adherence and outcomes. The presence of robust healthcare systems further facilitates market growth in this region.

- The European Medicines Agency (EMA) oversees the scientific evaluation of medicines across the 27 European Union Member States, supporting timely approval of innovative respiratory therapies and combination inhalation products. Its harmonized regulatory framework promotes patient safety, accelerates access to advanced asthma treatments, and strengthens the adoption of innovative asthma devices throughout Europe.

### Asia-Pacific : Emerging Market with Potential

Asia-Pacific is an emerging powerhouse in the market, holding approximately 20% of the global share. The region is experiencing rapid urbanization, leading to increased air pollution and a higher prevalence of asthma. Governments are implementing initiatives to improve healthcare access and awareness, which are key drivers for market growth. Regulatory bodies are also beginning to streamline approval processes for new devices, fostering innovation in the sector.

Countries like China, India, and Japan are at the forefront of this growth, with significant investments in healthcare infrastructure. The competitive landscape features both global players and local manufacturers, with companies like Omron Healthcare and Philips leading the charge. The increasing adoption of digital health technologies and telemedicine is also shaping the market, as patients seek more convenient and effective asthma management solutions. This trend is expected to continue as healthcare systems evolve in the region.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa (MEA) region represents a smaller segment of The global market, accounting for approximately 10% of the share. However, it is characterized by significant growth potential due to rising asthma prevalence and increasing healthcare investments. Governments are focusing on improving healthcare infrastructure and access, which is expected to drive demand for asthma devices. Regulatory bodies are also beginning to establish frameworks to facilitate the introduction of innovative products in the market. 

Leading countries in this region include South Africa, Saudi Arabia, and the UAE, where healthcare reforms are underway. The competitive landscape is evolving, with both international and local companies vying for market share. Key players are increasingly focusing on partnerships and collaborations to enhance their product offerings and reach underserved populations. The growing awareness of respiratory diseases is also contributing to the market's expansion in MEA.

## Competitive Benchmarking

The Global Asthma Devices is currently characterized by a dynamic competitive landscape, driven by increasing prevalence of asthma and a growing emphasis on innovative treatment solutions. Key players such as GlaxoSmithKline (GB), AstraZeneca (GB), and Boehringer Ingelheim (DE) are strategically positioning themselves through a combination of product innovation, partnerships, and regional expansion. These companies are not only focusing on enhancing their existing product lines but are also investing in research and development to introduce advanced devices that cater to the evolving needs of patients. This collective focus on innovation and strategic collaborations is shaping a competitive environment that is increasingly centered around patient-centric solutions and technological advancements.
 
In terms of business tactics, companies are localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies like Novartis (CH) and Teva Pharmaceutical Industries (IL) is significant, as they leverage their extensive distribution networks and established brand reputations to maintain competitive advantages. This competitive structure suggests that while there is room for smaller players, the dominance of key players is likely to shape market dynamics in the foreseeable future.
 
In August 2025, AstraZeneca (GB) announced a strategic partnership with a leading digital health company to integrate AI-driven analytics into their asthma management devices. This collaboration aims to enhance patient engagement and adherence to treatment protocols, indicating a shift towards more personalized healthcare solutions. The strategic importance of this move lies in its potential to improve patient outcomes and streamline the management of asthma, thereby reinforcing AstraZeneca's position as a leader in the market.
 
In September 2025, GlaxoSmithKline (GB) launched a new line of smart inhalers equipped with IoT technology, designed to provide real-time data on medication usage. This innovation not only addresses the need for better adherence but also aligns with the growing trend of digital health solutions. The introduction of these devices is likely to enhance patient monitoring and support healthcare providers in delivering more effective asthma management.
In October 2025, Boehringer Ingelheim (DE) expanded its product portfolio by acquiring a startup specializing in wearable asthma monitoring technology. This acquisition is expected to bolster Boehringer Ingelheim's capabilities in the digital health space, allowing the company to offer comprehensive solutions that integrate medication delivery with real-time health monitoring. Such strategic moves reflect a broader trend towards the convergence of pharmaceuticals and digital health, which is becoming increasingly vital in the asthma devices market.
 
As of October 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence within asthma management solutions. Strategic alliances are playing a crucial role in shaping the landscape, as companies seek to leverage complementary strengths to enhance their offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of agility and responsiveness in meeting patient needs.

## Report Scope

| MARKET SIZE 2024 | 4.268(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 4.555(USD Billion) |
| MARKET SIZE 2035 | 8.72(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.71% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | GlaxoSmithKline (GB), AstraZeneca (GB), Boehringer Ingelheim (DE), Novartis (CH), Teva Pharmaceutical Industries (IL), Merck & Co. (US), Sanofi (FR), Roche (CH), Philips (NL), Omron Healthcare (JP) |
| Segments Covered | Type, Technology, End Users |
| Key Market Opportunities | Integration of smart technology in asthma devices enhances patient adherence and management. |
| Key Market Dynamics | Technological advancements in inhaler design enhance patient adherence and reshape competitive dynamics in asthma management. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of The Global Asthma Devices by 2035?**
A: The projected market valuation for The Global Asthma Devices is expected to reach 8.72 USD Billion by 2035.

**Q: What was the market valuation of The Global Asthma Devices in 2024?**
A: The overall market valuation of The Global Asthma Devices was 4.268 USD Billion in 2024.

**Q: What is the expected CAGR for The Global Asthma Devices during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Asthma Devices during the forecast period 2025 - 2035 is 6.71%.

**Q: Which companies are considered key players in The Global Asthma Devices?**
A: Key players in The Global Asthma Devices include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceutical Industries.

**Q: What are the projected revenues for inhalers in The Global Asthma Devices by 2035?**
A: The projected revenue for inhalers in The Global Asthma Devices is expected to increase from 2.5 USD Billion to 5.2 USD Billion by 2035.

**Q: How do digitally operated inhaler devices compare to manually operated ones in terms of market growth?**
A: Digitally operated inhaler devices are projected to grow from 1.5 USD Billion to 3.5 USD Billion, whereas manually operated inhaler devices are expected to rise from 1.5 USD Billion to 3.0 USD Billion by 2035.

**Q: What is the expected revenue growth for nebulizers in The Global Asthma Devices?**
A: The expected revenue for nebulizers is projected to grow from 1.2 USD Billion to 2.5 USD Billion by 2035.

**Q: Which end-user segment is anticipated to have the highest revenue growth in The Global Asthma Devices?**
A: The hospital segment is anticipated to have the highest revenue growth, increasing from 1.5 USD Billion to 3.1 USD Billion by 2035.

**Q: What is the projected revenue for retail pharmacies in The Global Asthma Devices by 2035?**
A: The projected revenue for retail pharmacies in The Global Asthma Devices is expected to rise from 0.9 USD Billion to 1.8 USD Billion by 2035.

**Q: What are the expected revenue figures for the 'Others' category in the technology segment by 2035?**
A: The expected revenue for the 'Others' category in the technology segment is projected to increase from 1.268 USD Billion to 2.22 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/asthma-devices-market-1624*